# Supernus Announces First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/SUPN/supernus-announces-first-quarter-2026-financial-results
Ticker: SUPN
Company: Supernus
Source: Supernus
Published: 2026-05-05 20:05 EST
Original Source URL: https://ir.supernus.com
## Summary

Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year.

## Article Body
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year.
## Recent Company News
- 2026-05-27 20:30 EST — [Supernus Pharmaceuticals to Participate in June Investor Conferences](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-june-investor-conferences) — Source: Supernus
- 2026-05-06 21:00 EST — [Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-the-bank-of-america-2026-health-care-conference) — Source: Supernus
- 2026-05-05 20:05 EST — [Supernus Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/SUPN/supernus-announces-first-quarter-2026-financial-results) — Source: Supernus
- 2026-04-22 20:15 EST — [Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026) — Source: Supernus
- 2026-02-24 21:05 EST — [Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/SUPN/supernus-announces-record-fourth-quarter-and-full-year-2025-financial-results) — Source: Supernus
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)